전이성 거세 저항성 전립선 암 (MCRPC)을 치료하기위한 Ifinatamab deruxtecan 기반 치료 조합의 임상 연구 (MK-2400-01A/Ideate-Prostate02)
MK-2400-01A Substudy : MK-2400-U01 MSTRATES 기반 치료 조합 또는 IFINATAMAB DERUXECAN 단독 (MCRPC) (MCRPC) (MCRPC) (IDEATE-Proste02).
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Toll Free Number
- 전화번호: 1-888-577-8839
- 이메일: Trialsites@msd.com
연구 장소
-
-
Gelderland
-
Ede, Gelderland, 네덜란드, 6716 RP
- 모병
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
연락하다:
- Study Coordinator
- 전화번호: +31 318 435499
-
Nijmegen, Gelderland, 네덜란드, 6525 GA
- 모병
- UMC St. Radboud ( Site 0679)
-
연락하다:
- Study Coordinator
- 전화번호: +31 24 361 1111
-
-
Provincie Friesland
-
Drachten, Provincie Friesland, 네덜란드, 9202 NN
- 모병
- Nij Smellinghe ( Site 0684)
-
연락하다:
- Study Coordinator
- 전화번호: 0512 588 888
-
-
-
-
-
Auckland, 뉴질랜드, 1023
- 모병
- Auckland City Hospital ( Site 0831)
-
연락하다:
- Study Coordinator
- 전화번호: +6493074949
-
-
-
-
-
Taichung, 대만, 40705
- 모병
- Taichung Veterans General Hospital ( Site 0902)
-
연락하다:
- Study Coordinator
- 전화번호: +886423592525
-
Taipei, 대만, 11217
- 모병
- Taipei Veterans General Hospital ( Site 0901)
-
연락하다:
- Study Coordinator
- 전화번호: +886228712121
-
-
-
-
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center ( Site 0926)
-
연락하다:
- Study Coordinator
- 전화번호: +82234103459
-
Seoul, 대한민국, 03722
- 모집하지 않고 적극적으로
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu, Seoul, 대한민국, 05505
- 모병
- Asan Medical Center ( Site 0925)
-
연락하다:
- Study Coordinator
- 전화번호: +82230105977
-
-
-
-
-
Hamburg, 독일, 20246
- 모병
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
연락하다:
- Study Coordinator
- 전화번호: +4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, 독일, 69120
- 모병
- NCT ( Site 0528)
-
연락하다:
- Study Coordinator
- 전화번호: 00496221566857
-
Ulm, Baden-Wurttemberg, 독일, 89081
- 모병
- Universitaetsklinikum Ulm. ( Site 0530)
-
연락하다:
- Study Coordinator
- 전화번호: +4973150058188
-
-
Thuringia
-
Jena, Thuringia, 독일, 07747
- 모병
- Universitaetsklinikum Jena ( Site 0525)
-
연락하다:
- Study Coordinator
- 전화번호: +49-3641-9-329901
-
-
-
-
California
-
Los Angeles, California, 미국, 90095
- 모병
- UCLA Hematology & Oncology ( Site 0003)
-
연락하다:
- Study Coordinator
- 전화번호: 310-829-5471
-
Orange, California, 미국, 92868
- 모병
- University of California-Irvine Medical Center ( Site 0016)
-
연락하다:
- Study Coordinator
- 전화번호: 714-456-5153
-
San Francisco, California, 미국, 94158
- 모병
- UCSF Medical Center at Mission Bay ( Site 0034)
-
연락하다:
- Study Coordinator
- 전화번호: 415-502-2097
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
연락하다:
- Study Coordinator
- 전화번호: 202-877-3061
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan ( Site 0021)
-
연락하다:
- Study Coordinator
- 전화번호: 734-936-4000
-
-
New York
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
연락하다:
- Study Coordinator
- 전화번호: 347-798-8620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- 모병
- UPMC Hillman Cancer Center ( Site 0014)
-
연락하다:
- Study Coordinator
- 전화번호: 412-647-2811
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138
- 모병
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
연락하다:
- Study Coordinator
- 전화번호: 901-683-0055
-
-
Washington
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center ( Site 0013)
-
연락하다:
- Study Coordinator
- 전화번호: 206-288-1111
-
-
-
-
-
São Paulo, 브라질, 01221-020
- 모병
- IPITEC ( Site 0275)
-
연락하다:
- Study Coordinator
- 전화번호: +551194322-6006
-
São Paulo, 브라질, 03102-006
- 모병
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
연락하다:
- Study Coordinator
- 전화번호: +551144500360
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, 브라질, 59062-000
- 모병
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
연락하다:
- Study Coordinator
- 전화번호: (84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-001
- 모병
- Hospital Moinhos de Vento ( Site 0278)
-
연락하다:
- Study Coordinator
- 전화번호: +55 51 3314-3209
-
Porto Alegre, Rio Grande do Sul, 브라질, 90020-090
- 모병
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
연락하다:
- Study Coordinator
- 전화번호: +555132148151
-
-
São Paulo
-
Bragança Paulista, São Paulo, 브라질, 12916-542
- 모병
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
연락하다:
- Study Coordinator
- 전화번호: +551124901366
-
Ribeirão Preto, São Paulo, 브라질, 14048900
- 모병
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
연락하다:
- Study Coordinator
- 전화번호: (16) 3963-6487
-
São José do Rio Preto, São Paulo, 브라질, 15090-000
- 모병
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
연락하다:
- Study Coordinator
- 전화번호: +55 17 99625-3919
-
São Paulo, São Paulo, 브라질, 01327-001
- 모병
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
연락하다:
- Study Coordinator
- 전화번호: 55 11 3549-0009
-
-
-
-
-
Madrid, 스페인, 28034
- 모병
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
연락하다:
- Study Coordinator
- 전화번호: +34913368263
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre ( Site 0622)
-
연락하다:
- Study Coordinator
- 전화번호: +34608464547
-
Madrid, 스페인, 28040
- 모병
- Hospital Clinico San Carlos ( Site 0618)
-
연락하다:
- Study Coordinator
- 전화번호: +34913303546
-
Seville, 스페인, 41013
- 모병
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
연락하다:
- Study Coordinator
- 전화번호: +34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat, Barcelona, 스페인, 08908
- 모병
- ICO L Hospitalet ( Site 0617)
-
연락하다:
- Study Coordinator
- 전화번호: +34932607744
-
-
-
-
-
La Rioja, 아르헨티나, F5300COE
- 모병
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
연락하다:
- Study Coordinator
- 전화번호: 54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, C1426ANZ
- 모병
- Instituto Alexander Fleming ( Site 0202)
-
연락하다:
- Study Coordinator
- 전화번호: 5411 3221 8900
-
-
-
-
-
Dublin, 아일랜드, D09 V2N0
- 모병
- Beaumont Hospital, Dublin ( Site 0465)
-
연락하다:
- Study Coordinator
- 전화번호: 0035318092010
-
Dublin, 아일랜드, D24 NR0A
- 모병
- Tallaght University Hospital ( Site 0462)
-
연락하다:
- Study Coordinator
- 전화번호: 0035314144209
-
-
Dublin
-
Dublin, Dublin, 아일랜드, D04 T6F4
- 모병
- St Vincent's University Hospital ( Site 0463)
-
연락하다:
- Study Coordinator
- 전화번호: +353 1 221 4982
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, 영국, CB2 2QQ
- 모병
- Addenbrooke's Hospital ( Site 0747)
-
연락하다:
- Study Coordinator
- 전화번호: 00441223216083
-
-
London, City of
-
London, London, City of, 영국, NW3 2QG
- 모병
- Royal Free Hospital ( Site 0743)
-
연락하다:
- Study Coordinator
- 전화번호: 00442077940500/2237
-
London, London, City of, 영국, EC1A 7BE
- 모병
- St Bartholomew's Hospital ( Site 0749)
-
연락하다:
- Study Coordinator
- 전화번호: 00442073777000
-
-
Surrey
-
London, Surrey, 영국, SM3 5PT
- 모병
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
연락하다:
- Study Coordinator
- 전화번호: 0203 437 3500
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus ( Site 0400)
-
연락하다:
- Study Coordinator
- 전화번호: 972(47776234)
-
Jerusalem, 이스라엘, 9112001
- 모병
- Hadassah Medical Center ( Site 0404)
-
연락하다:
- Study Coordinator
- 전화번호: +97226777333
-
Petah Tikva, 이스라엘, 4941492
- 모병
- Rabin Medical Center ( Site 0402)
-
연락하다:
- Study Coordinator
- 전화번호: +972544594048
-
Ramat Gan, 이스라엘, 5265601
- 모병
- Sheba Medical Center ( Site 0401)
-
연락하다:
- Study Coordinator
- 전화번호: +97235303030
-
Tel Aviv, 이스라엘, 6423906
- 모병
- Sourasky Medical Center ( Site 0403)
-
연락하다:
- Study Coordinator
- 전화번호: +97236947832
-
-
-
-
-
Brescia, 이탈리아, 25123
- 모집하지 않고 적극적으로
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan, 이탈리아, 20133
- 모병
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
연락하다:
- Study Coordinator
- 전화번호: +390223904449
-
Naples, 이탈리아, 80131
- 모병
- A.O.U. Federico II di Napoli ( Site 0435)
-
연락하다:
- Study Coordinator
- 전화번호: +390817463660
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
연락하다:
- Study Coordinator
- 전화번호: +390630155202
-
-
Torino
-
Orbassano, Torino, 이탈리아, 10143
- 모병
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
연락하다:
- Study Coordinator
- 전화번호: 00390119026534
-
-
-
-
Maule Region
-
Talca, Maule Region, 칠레, 3465584
- 모병
- Clinica Universidad Catolica del Maule ( Site 0236)
-
연락하다:
- Study Coordinator
- 전화번호: 56992992913
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, 칠레, 8420383
- 모병
- Bradfordhill ( Site 0231)
-
연락하다:
- Study Coordinator
- 전화번호: +56229490970
-
Santiago, Region M. de Santiago, 칠레, 7560908
- 모병
- Centro de Oncología de Precisión ( Site 0241)
-
연락하다:
- Study Coordinator
- 전화번호: +56225189885
-
Santiago, Region M. de Santiago, 칠레, 7500921
- 모병
- Fundación Arturo López Pérez ( Site 0232)
-
연락하다:
- Study Coordinator
- 전화번호: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, 칠레, 2520598
- 모병
- ONCOCENTRO APYS ( Site 0234)
-
연락하다:
- Study Coordinator
- 전화번호: +56323320850
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- 모병
- BC Cancer - Vancouver Center ( Site 0103)
-
연락하다:
- Study Coordinator
- 전화번호: 6048776000
-
-
Ontario
-
Toronto, Ontario, 캐나다, M4N 3M5
- 모병
- Sunnybrook Research Institute ( Site 0109)
-
연락하다:
- Study Coordinator
- 전화번호: 4164806100
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- Princess Margaret Cancer Centre ( Site 0102)
-
연락하다:
- Study Coordinator
- 전화번호: 4169464501
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3T 1E2
- 모병
- Jewish General Hospital ( Site 0108)
-
연락하다:
- Study Coordinator
- 전화번호: 5143408110
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
연락하다:
- Study Coordinator
- 전화번호: 8197802222
-
-
-
-
-
Adana, 터키 (Türkiye), 01250
- 모병
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
연락하다:
- Study Coordinator
- 전화번호: +903223271274
-
Ankara, 터키 (Türkiye), 06230
- 모병
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
연락하다:
- Study Coordinator
- 전화번호: +90 312 305 50 00
-
Ankara, 터키 (Türkiye), 06800
- 모병
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
연락하다:
- Study Coordinator
- 전화번호: +903125526000
-
Ankara, 터키 (Türkiye), 06620
- 모병
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
연락하다:
- Study Coordinator
- 전화번호: +903122126040
-
Istanbul, 터키 (Türkiye), 34010
- 모병
- Koç Üniversitesi Hastanesi ( Site 0656)
-
연락하다:
- Study Coordinator
- 전화번호: +905369410661
-
Istanbul, 터키 (Türkiye), 34098
- 모병
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
연락하다:
- Study Coordinator
- 전화번호: +902124143000
-
Rize, 터키 (Türkiye), 53020
- 모병
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
연락하다:
- Study Coordinator
- 전화번호: +904642130491
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, 폴란드, 60-355
- 모병
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
연락하다:
- Study Coordinator
- 전화번호: +61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, 폴란드, 02-781
- 모병
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
연락하다:
- Study Coordinator
- 전화번호: +48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, 폴란드, 80-214
- 모병
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
연락하다:
- Study Coordinator
- 전화번호: +48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, 폴란드, 75-581
- 모병
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
연락하다:
- Study Coordinator
- 전화번호: +48943488930
-
-
-
-
Gironde
-
Bordeaux, Gironde, 프랑스, 33000
- 모병
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
연락하다:
- Study Coordinator
- 전화번호: +33556333261
-
-
Nord
-
Lille, Nord, 프랑스, 59000
- 모병
- Centre Oscar Lambret ( Site 0495)
-
연락하다:
- Study Coordinator
- 전화번호: +333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, 프랑스, 44800
- 모병
- Institut De Cancerologie De L Ouest ( Site 0494)
-
연락하다:
- Study Coordinator
- 전화번호: +33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne, Pyrenees-Atlantiques, 프랑스, 64100
- 모병
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
연락하다:
- Study Coordinator
- 전화번호: +33559443762
-
-
Rhone
-
Pierre-Bénite, Rhone, 프랑스, 69310
- 모병
- centre hospitalier lyon sud ( Site 0497)
-
연락하다:
- Study Coordinator
- 전화번호: 33 4 78 86 43 24
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, 호주, 2109
- 모병
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
연락하다:
- Study Coordinator
- 전화번호: +61 2 9812 2956
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
실험적: Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
다른 이름들:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
실험적: I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
다른 이름들:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
다른 이름들:
|
|
실험적: I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
다른 이름들:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
기간: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
기간: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
기간: Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
기간: Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
기간: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
기간: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
기간: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
기간: Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
기간: Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
기간: Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
기간: Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
기간: Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
기간: Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 책임자: Medical Director, Merck Sharp & Dohme LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2400-01A
- MK-2400-01A (기타 식별자: MSD)
- U1111-1310-5406 (레지스트리 식별자: UTN)
- IDeate-Prostate02 (기타 식별자: MSD)
- 2024-516036-94-00 (레지스트리 식별자: EU CT)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .